Communiqués ArcticZymes Technologies ASA

Actions

AZT

NO0010014632

Produits pharmaceutiques

Marché Fermé - Oslo Bors 16:45:00 05/10/2026			Varia. 5j.	Varia. 1 janv.
20,60 ^NOK	+3,52%		+3,00%	-

07/09	Arctic entame le suivi d'ArcticZymes Technologies avec une recommandation à l'achat et un objectif de cours de 26 couronnes norvégiennes	FW
18/08	Transcript : ArcticZymes Technologies ASA, Q2 2026 Earnings Call, Aug 14, 2026

Communiqués

01/10	ArcticZymes Technologies ASA to present at the Swiss Nordic Bio 2026 Conference	AQ
02/09	ArcticZymes Technologies ASA to present at the Pareto Securities' 17th Annual Healthcare Conference 2026	AQ
14/08	ArcticZymes Technologies Delivers 19% Sales Growth (29% CER) and NOK 7.4 Million EBITDA in Q2 2026	AQ
07/08	ArcticZymes Technologies ASA: Invitation to presentation of Q2 and 6M 2026 results	AQ
28/05	ArcticZymes Technologies Strengthens Board with Appointment of Dr. Hanna Pirita Lesch, Supporting Diversification into RNA and Continued Leadership in Cell & Gene Therapy	AQ
28/05	ArcticZymes Technologies ASA - Minutes form Annual General Meeting 2026	AQ
07/05	ArcticZymes Technologies Delivers 36% Sales Growth in Q1 2026, with Molecular Tools Rebound and Biomanufacturing Momentum	AQ
06/05	ArcticZymes Technologies ASA: Notice of Annual General Meeting	AQ
04/05	ArcticZymes Technologies ASA: Invitation to presentation of Q1 2026	AQ
30/04	ArcticZymes Technologies ASA - Annual Report and ESG report for 2025	AQ
30/04	ArcticZymes Technologies strengthens IP platform with new patent grant supporting expansion into RNA therapeutics manufacturing	AQ
28/04	ArcticZymes Expands acib Collaboration and Joins CAARE Consortium to Advance Viral Vector Bioprocessing	AQ
06/03	ArcticZymes Technologies ASA - Capital Markets Day 2026. Scaling a High-Performance Enzyme Platform for Compounding Growth	AQ
03/03	ArcticZymes Technologies ASA: Reminder - Capital Markets Day, 6 March 2026	AQ
03/03	ArcticZymes Technologies ASA: Reminder - Capital Markets Day, 6 March 2026	AQ
26/02	ArcticZymes Releases New White Paper Quantifying the Impact of Optimized Nuclease Strategy on Viral Vector Manufacturing Economics	AQ
12/02	ArcticZymes Technologies Reports Strong Q4 and FY 2025. Accelerating Sales Growth and Improved Profitability	AQ
11/02	ArcticZymes Technologies ASA - Invitation to Capital Markets Day 2026	AQ
05/02	ArcticZymes Technologies ASA: Invitation to presentation of Q4 and FY 2025 results	AQ
04/12	ArcticZymes Technologies : Sell Shares to Support Employee Share Purchase Program	PU
28/11	ArcticZymes Technologies Completes Share Buyback to Support Employee Share Purchase Program	AQ
25/11	ArcticZymes Technologies to present at DNB Carnegie Nordic Healthcare Conference	AQ
10/11	Long-Term Incentive Plan - grant of share options to primary insiders	AQ
06/11	ArcticZymes Technologies Reports Q3 2025 Results: Continued Growth Momentum and Strengthened Profitability	AQ
30/10/25	ArcticZymes Technologies ASA: Invitation to presentation of Q3 and 9M 2025 results	AQ